Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angeion v. Cardiac Pacemakers, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Magistrate judge recommends in a Report and Recommendation that a Minneapolis district court judge grant Angeion's motions for summary judgment and deny the Guidant subsidiary's counter motions for summary judgment of non-infringement that its Mini I and II automatic implantable cardioverter defibrillators infringe certain claims of three Angeion patents related to smaller size, smaller capacitance and "Hot Can-like" features of Angeion devices. The judge also recommends that a claim related to a fourth Angeion patent be dismissed. Angeion and CPI have up to twenty days to file responses to the report, after which time the district court judge will make a final ruling. A jury will consider sometime this fall claims of validity and enforceability of the patents, as well as any possible damages or willful infringement...

You may also be interested in...

France Moves To Bolster Drug Supplies Hit By COVID-19

France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.

Sun, Accord, Amneal And Apotex Donate Hydroxychloroquine

Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts